




I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 8, 2006

Signature: Andrea Silverman

(Andrea Silverman)

164 
Docket No.: AREX-P03-004
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Madiyalakan *et al.*

Application No.: 09/376,604

Confirmation No.: 6693

Filed: August 18, 1999

Art Unit: 1642

For: THERAPEUTIC COMPOSITIONS THAT
ALTER THE IMMUNE RESPONSE

Examiner: G. B. Nickol

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant submits herewith copies of the cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure statement shall not be construed to be an

3178189.1

03/15/2006 WABDELRI 00000021 181945 09376604

01 FC:1806

180.00 DA

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P03-004. A duplicate copy of this paper is enclosed.

Dated: March 8, 2006

Respectfully submitted,

By 
Gloria Fuentes

Registration No.: 47,580
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL For FY 2005

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00

Complete if Known

Application Number 09/376,604
Filing Date August 18, 1999
First Named Inventor Ragupathy Madiyalakan
Examiner Name G. B. Nickol
Art Unit 1642
Attorney Docket No. AREX-P03-004

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____
☒ Deposit Account Deposit Account Number: 18-1945 Deposit Account Name: Ropes & Gray LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims - 233 Extra Claims Fee (\$) Fee Paid (\$) Multiple Dependent Claims
- 233 x = Fee (\$) Fee Paid (\$)
Indep. Claims Extra Claims Fee (\$) Fee Paid (\$)
- 11 x =

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)
- 100 = /50 (round up to a whole number) x =

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

SUBMITTED BY

Signature Gloria Fuentes Registration No. (Attorney/Agent) 47,580 Telephone (617) 951-7000
Name (Print/Type) Gloria Fuentes Date March 8, 2006

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 8, 2006 Signature: Andrea Silverman (Andrea Silverman)



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	09/376,604	
			Filing Date	August 18, 1999	
			First Named Inventor	Ragupathy Madiyalakan	
			Art Unit	1642	
			Examiner Name	G. B. Nickol	
Sheet	1	of	2	Attorney Docket Number	AREX-P03-004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,240,833	08-31-93	Nudelman	
	AC	US-5,807,978	09-15-98	Kokolus	
	AD	US-6,088,613	07-11-00	Unger	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP 0 153 871 A2	09-04-1985	Chang		
	BB	EP 0 315 456 B1	05-10-1987	Fagnani		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	ALGARRA et al., 1997, Altered MHC class I antigens in tumors, Int. J. of Clin & Lab. Res. 27:95-102 (Abstract only)			
	CB	ANTONIA et al., 1995, Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein, Int. Immunol. 7(5):715-725			
	CC	BAUM, 1994, Activating Anti-Idiotypic Human Anti-Mouse Antibodies for Immunotherapy of Ovarian Carcinoma, Cancer 73:1121-1125			
	CD	BENICHOU et al., 1994, Disruption of the determinant hierarchy on a self-MHC peptide: concomitant tolerance induction to the dominant determinant and priming to the cryptic self-determinant, Int. Immunol. 6(1):131-138			
	CE	BODEY et al., 2000, Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy, Anticancer Res. 20:2665-2676			
	CF	CIBOTTI et al., 1992, Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants, Proc. Natl. Acad. Sci. USA 89:416-420			
	CG	GOLUMBEK et al., 1993, The Antitumor Immune-Response as a Problem of Self-Non-Self Discrimination – Implications for Immunotherapy, Immunologic Res. 12:183-192 (Abstract only)			
	CH	JACOBS and HASKELL, 1991, Clinical Use of Tumor Markers in Oncology, Curr. Probl Cancer 15(6):299-360			
	CI	LANZAVECCHIA, 1996, Mechanisms of antigen uptake for presentation, Curr. Opin. Imm. 8:348-354			
	CJ	LEE et al., 1999, Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression, J. Immunol. 163:6292-6300			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/376,604
				Filing Date	August 18, 1999
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1642
				Examiner Name	G. B. Nickol
Sheet	2	of	2	Attorney Docket Number	AREX-P03-004

	CK	NISHIMURA et al., 2000, The critical role of TH1-dominant immunity in tumor immunology, Cancer Chemother. Pharmacol. 46(Suppl):S52-S61	
	CL	ÖHLÉN et al., 2001, Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CB ⁺ T Cells of CTL Immunotherapy of Tumors Expressing the Antigen, J. Immunol. 166:2863-2870	
	CM	PANI, 1994, Failure of presented, nondominant self epitope to induce tolerance – implications for autoimmune-diseases, Immunological Investigations 23:337-346 (Abstract only)	
	CN	SEMINO et al., 1993, Heterogeneity of the alpha-interferon-mediated overexpression of class-I and class-II major histocompatibility complex molecules in primary cultured cancer cells, J. Biol. Reg. & Homeo. Agents 7:99-105	
	CO	WATTS and LANZAVECCHIA, 1993, Suppressive Effect of Antibody on Processing of T Cell Epitopes, J. Exp. Med. 178:1459-1463	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--